繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-810 (SAFETYNADOL)

SNP-810 (SAFETYNADOL)

Indication
Hepatotoxicity-free Acetaminophen (Analgesic and antipyretic)
Product Advantages
1. Hepatotoxicity-free
2. To address the important and urgent unmet medical needs
3. A patented formulation with great safety margin
Status
Phase I low-dose, high-dose completed (Pivotal trial applying for USFDA NDA)
Competitive Edge
1. Currently, no hepatotoxicity-free acetaminophen on the market
2. Great impact on the market share of pain controllers, especially to NSAIDS, Cox2 inhibitors and opioids
3. Reduction of lawsuit and compensation
Potential Market
Acetaminophen sales are 1.3 billion USD a year (US only)

Mechanism of Action of SNP-810 and NAC


陕西快乐十分中奖技巧 炸金花提现版 黑龙江省体彩11选5 南京好运麻将正版 国标麻将单机版下载app 北京快中彩玩法说明 北京快三和值玩法 2020马会资料精选免费大全 街机捕鱼机器 代理麻将斗地主棋牌app 金博棋牌app 彩票开奖查询30选5 十一选五每天必出号码 看今晚的四不像图+正版 河南十一选五赔奖率 gpk捕鱼大富翁技巧 qq游戏山东麻将下载